Imaging is a key technology in the early detection of cancers, including X-ray
mammography, low-dose CT for lung cancer, or optical imaging for skin, esophageal, or …

Prostate cancer (PCa) is the most widely diagnosed male cancer in the Western World and
while low-and intermediate-risk PCa patients have a variety of treatment options, metastatic …

Personalized medicine (PM) is about tailoring a treatment as individualized as the disease.
The approach relies on identifying genetic, epigenomic, and clinical information that allows …

Therapeutic interventions for advanced prostate cancer (PCa) center on inhibiting androgen
receptor (AR) and downstream signaling pathways. Resistance to androgen deprivation …

Introduction: Extracellular vesicles (EVs) have emerged as a very attractive source of cancer-
derived RNA biomarkers for the early detection, prognosis and monitoring of various …

Given the low specificity of the routinely used biomarker prostate-specific antigen, circulating
tumor cell (CTC) enumeration seems to be particularly useful in the monitoring of prostate …

Background Prostate cancer is a common cancer but is oftentimes slow growing. When
confined to the prostate, radical prostatectomy (RP), which involves removal of the prostate …

Objectives To investigate whether diffusion-weighted imaging (DWI) apparent diffusion
coefficient (ADC) correlates with prostate cancer aggressiveness and further to compare the …

The vast majority of new prostate cancer diagnoses are low-grade tumors that are monitored
by active surveillance rather than undergoing immediate treatment. However, a subset of …

Proxalutamide is a newly developed androgen receptor (AR) antagonist for the treatment of
castration-resistant prostate cancer (PCa) that has entered phase III clinical trials. In the …